Anti-Proliferative Properties of the Novel Hybrid Drug Met-ITC, Composed of the Native Drug Metformin with the Addition of an Isothiocyanate H(2)S Donor Moiety, in Different Cancer Cell Lines

Metformin (Met) is the first-line therapy in type 2 diabetes mellitus but, in last few years, it has also been evaluated as anti-cancer agent. Several pathways, such as AMPK or PI3K/Akt/mTOR, are likely to be involved in the anti-cancer Met activity. In addition, hydrogen sulfide (H(2)S) and H(2)S d...

Descripción completa

Detalles Bibliográficos
Autores principales: Citi, Valentina, Barresi, Elisabetta, Piragine, Eugenia, Spezzini, Jacopo, Testai, Lara, Da Settimo, Federico, Martelli, Alma, Taliani, Sabrina, Calderone, Vincenzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10671447/
https://www.ncbi.nlm.nih.gov/pubmed/38003321
http://dx.doi.org/10.3390/ijms242216131

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10671447/
https://www.ncbi.nlm.nih.gov/pubmed/38003321
http://dx.doi.org/10.3390/ijms242216131

Ejemplares similares